Growing Multiple Sclerosis Treatment Knowledge: Luc Truyen, MD, PhD


The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.

"I don’t think we have enough data on hand to start tailoring specific regimens for specific subsets in an emerging field where all is not created equal.”

The multiple sclerosis (MS) community has benefitted over the last few years from an influx of FDA-approved therapeutic treatment options, as well as a better growing understanding of how to diagnose the disease and which mechanisms needed to target. New treatments have helped reduce the long-term disability of the disease, but there still remains no cure or clear ways to prevent the disease from developing.

There are currently about 2.8 million individuals worldwide that live with MS, making it the leading cause of nontraumatic neurological disability. Additionally, there are a number of different types of MS, each with differing timetables of disease progression. While our knowledge of the disease has certainly grown, there are areas that still need further examination, according to Luc Truyen, MD, PhD.

Ahead of the ACTRIMS Forum 2021, February 25-27, Truyen, the global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical, sat down with NeurologyLive to provide a brief summary of the knowledge gained on the disease in the past decade and where it needs to continue to grow.

For more coverage of ACTRIMS 2021, click here.

Related Videos
Sanjay R. Patel, MD, MS
Patricia K. Coyle, MD
Video 2 - 5 KOLs are featured in "Natural History of Spinal Muscular Atrophy"
Video 1 - 5 KOLs are featured in "Clinical Features and Phenotypes of Spinal Muscular Atrophy"
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
© 2024 MJH Life Sciences

All rights reserved.